Clinical trial
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT04614194
Study timeline
Study start (actual)2021-04-15Date precision: day
Registry last updated2026-06-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
LetrozoleDRUG · verified · RxNorm: letrozole
AbemaciclibDRUG · verified · RxNorm: abemaciclib
Sponsors & collaborators
University of Texas Southwestern Medical Centerlead sponsor
Eli Lilly and Companycollaborator
Cancer Prevention Research Institute of Texascollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04614194 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.